BioSpace News Archive

United Therapeutics Corporation announced that Mr. James Edgemond, Chief Financial Officer and Treasurer of United Therapeutics, will provide an overview and update on the company’s business during a fireside chat session at the Jefferies Virtual Health Care Conference.

Additionally, Announces Accretive Acquisition of ActivStyle, a Home Medical Supply Provider

SpringWorks Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, announced the appointment of Julie Hambleton, M.D. to the Company’s Board of Directors.

Tissue from presymptomatic patient in Italy was found to contain SARS-CoV-2 using Company’s Logix Smart™ COVID-19 test kit

Anokion SA, a Swiss biotechnology company focused on treating autoimmune disease by restoring normal immune tolerance, announced that management will participate in the Jefferies 2020 Virtual Healthcare Conference being held from June 2-4, 2020.

Merck to Apply its Industry-Leading Vaccine Development Capabilities to SARS-CoV-2 Vaccine Program Originated by Themis and Institut Pasteur

Albireo Pharma, Inc., a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, announced that Ron Cooper, President and Chief Executive Officer, will present via webcast at the 2020 Jefferies Virtual Healthcare Conference on Tuesday, June 2, at 8:30 a.m. EDT.

Principia Biopharma Inc. announced upcoming presentations at the European Hematology Association and the International Society on Thrombosis and Haemostasis congresses from Principia’s clinical program evaluating rilzabrutinib in patients with immune thrombocytopenia, a rare autoimmune disease that causes high risk for bleeding, excessive bruising, fatigue and potential for life threatening intracranial bleeding due to destruction of platelets.

Quotient Limited, a commercial-stage diagnostics company, announced that financial results for its fiscal fourth quarter and full year ended March 31, 2020 will be released before market open on Tuesday, June 9, 2020.

First U.S. study to feature double-blinded, controlled, randomized trial design with safety and oxygenation endpoints